An interventional study of Total Contact Cast and Posterior Slab in Charcot Neuroarthropathy, sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh. Recruiting at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-22.
Sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Diabetic Foot with a site in India — 2 open to participants now, 2 under way, none of them phase 3. Diabetic Foot · India.
Among the 18 studies in Diabetic Foot with a site in India, this one is the 11th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2024, is one of 7 with no phase, and was the 15th registered.
1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.
Browse Diabetic Foot studies →2 of the 18 studies in Diabetic Foot with a site in India are open now. Recruiting first, the newest first:
Adichunchanagiri Institute of Medical Sciences, B G Nagara · Sites in India, Bangladesh
Ages 18–75
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 4 · Phase 4 1
First in 2007; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 60 across 849 interventional studies indexed under Diabetic Foot.
Median enrollment 120 across the 17 interventional studies, 200 across the 1 observational. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 18 have an industry lead sponsor. The 10 most frequent:
Post Graduate Institute of Medical Education and Research, Chandigarh is the lead sponsor of 298 studies on the registry; 43 are open to participants now.
Post Graduate Institute of Medical Education and Research, Chandigarh has 3 studies filed under Diabetic Foot — fewer than ten, so there is no comparison to draw.
1 of the studies in Diabetic Foot with a site in India that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07781917Adichunchanagiri Institute of Medical Sciences, B G NagaraHPTC Versus AFSM in Diabetic Foot Ulcers | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Diabetic Foot with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Charcot neuroarthropathy (CN) is a condition in diabetic patients characterized by foot swelling, redness, and a temperature difference exceeding 2˚C compared to the other foot. The study compares two treatments: a standard knee-high, non-removable total contact cast (TCC) and a non-removable knee-high walker. Both aim to immobilize and offload the foot to promote healing. The study will involve diabetic patients with specific criteria and exclude those with conditions like foot ulcers or severe kidney issues. Patients will be randomly assigned to one of the two treatments and followed for up to a year. The primary goal is to see how many patients achieve remission within six months, with secondary goals including remission within twelve months, time to remission, quality of life, and foot health. Statistical tests will be used to analyze the data and determine the effectiveness of each treatment. The study aims to improve CN treatment and provide better options for patients.
Background:
The etiopathogenesis of Charcot neuroarthropathy (CN) is intriguing since its early description in 1868. Early elucidation for the causation of CN with the neurotraumatic and neurovascular theories were accurate in their times. Of late, the conceptual understanding of CN has evolved after description of the role of osteoclastic resorption of foot bones by activation of receptor activator of nuclear factor kappa-B (RANK). The activation of RANK by RANK ligand (RANKL) occurs as a result of recurrent trauma to an insensate foot inciting a pro-inflammatory cascade of multiple inflammatory cytokines locally, the most common being tumour necrosis factor-α (TNF-α), interleukin-1ß (IL-1β) and interleukin-6 resulting in a local 'cytokine storm'. In addition, non-inflammatory factors including hyperglycemic milieu by increasing advanced glycosylation end products (AGEs), and autonomic neuropathy by causing a decrease in calcitonin gene-related peptide (CGRP) and endothelial nitric oxide synthase, can upregulate the RANKL/ NF-кB pathway.
Active CN of foot is defined clinically as a localised swelling, erythema and temperature difference exceeding 2˚C compared to a similar site on the opposite foot. The knee high non-removable total contact cast (TCC) is preferred as the treatment for the management of active CN.
Problem Statement: TCC has inherent limitations including worsening of bone mineral density (BMD), cast-related tissue injury, shin ulcers and prolonged immobilization usually for 6 to 12 months) and adversely impact the quality of life of individuals with CNO. Moreover, TCC is associated with sweating, maceration, in-TCC skin ulceration and intolerance in hot weather of tropical countries.
A knee-high walker rendered non-removable is suggested as a second choice in order to immobilise and offload the foot as a conditional recommendation with low quality of evidence. Presently there are no randomized controlled head-to head comparison of these non-removable knee high devices for active CNO.
Hence, this shall be the first study to the best of our knowledge for head-to-head comparison of two different offloading strategies for active CNO.
Methods:
The diagnosis of active CN shall be further corroborated by X-ray and/or magnetic resonance imaging (MRI) (3T scanner Siemens MagnetromVerio). Sanders-Frykberg classification will be used for anatomical grading and localization of the involved site of the foot. A written informed consent shall be obtained from all participants.
Clinical details regarding duration of symptoms, inciting event, diabetes duration and coexisting microvascular and macrovascular diabetic complications will be recorded. Detailed neurological examination shall be performed including vibration perception threshold (VPT>25 mV was considered as abnormal) by biothesiometer-Vibrometer-VPT1(Diabetik Foot Care, Madras Engineering Service, India), 10-g monofilament (Diabetik Foot Care, Madras Engineering Service, India) perception at 5 standardized plantar sites and ankle reflex. Foot temperature shall be measured by infrared dermal thermometry (FLIR Systems Inc, Orlando, USA) with a pixel resolution of 4800 (80, 60), thermal sensitivity of \<0.15˚C and range of detection from -20˚C to 250˚C.
Blood sample for biochemistry, bone turnover markers (BTMs) and inflammatory cytokines shall be collected after an overnight fast (8-10 hours) and analysed by ECLIA.
All participants will be randomised by one of the investigators at each site using computer generated randomisation blocks in 1:1 to either receive standardised non-walking, non-removable, knee high, fibre-glass total contact cast (group A) or posterior non-removable knee high slab (group B) for immobilisation.
All participants will be followed fortnightly and change of cast shall be performed in view of 'pistoning' effect due to reduction of edema at each visit. An average of 3 temperature recordings at the ROI of foot will be obtained after the removal of cast for 30 minutes, during each follow up visit. Inflammatory cytokines, BTMs shall be evaluated at baseline and at clinical remission or 12 months (whichever occurred earlier). Clinical remission of active CN shall be defined as a temperature difference \<2˚C between the affected foot and a similar site (temperature obtained thrice) on the opposite foot on two successive follow-up visits two-four weeks apart.
Statistical analysis:
Normality of the data for each variable shall be assessed by Kolmogorov-Smirnov test. Data shall be expressed as mean ± SD if normally distributed and as median and inter-quartile range if skewed. Student T-test shall be used to compare the means of two groups for parametric data and Mann-Whitney U test for non-parametric data. Comparison of proportion of participants achieving remission shall be performed by Mc Nemar test.
A Kaplan-Meier curve shall be constructed to assess the difference in remission of active CN with the interventions. Cox proportion hazard model will be used to identify the association between the baseline variables and incident remission. The variables are decided by their clinical relevance to active CN of foot.
Sample Size: 80 patients are required to be 80% sure that the upper limit of a one-sided 95% confidence interval (or equivalently a 90% two-sided confidence interval) will exclude a difference in favour of the TCC of more than 20%.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
standardised non-walking, non-removable, knee high, fibre-glass total contact cast
Device: Total Contact Cast
posterior non-removable knee high slab
Device: Posterior Slab
Knee High Fiber Glass Total contact Cast
Posterior Slab Knee high non walking
Efficacy of posterior Slab
Proportion of participants achieving active CNO remission with Posterior slab compared to Total contact Cast
Time frame: 26 weeks
Proportion of participants achieving remission 48 weeks
Proportion of participants achieving remission within a duration of 12 months from randomization,
Time frame: 48 weeks
Time to achieve remission
Time (in weeks) to achieve remission as defined by dermal thermometry in two arms.
Time frame: 48 weeks
Life Quality 1
Foot Health Status Questionnaire Higher score means greator disability and lower score is better and outcome of interest; Score of 50 is poor and lesser than 10 is best
Time frame: 48 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Oct 2026, 22 months after the start.
Of 243 non-industry interventional studies with no phase under Diabetic Foot, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 22 months is close to that.
Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post Graduate Institute of Medical Education and Research, Chandigarh →